These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38147316)

  • 1. FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment.
    Knorr DA; Blanchard L; Leidner RS; Jensen SM; Meng R; Jones A; Ballesteros-Merino C; Bell RB; Baez M; Marino A; Sprott D; Bifulco CB; Piening B; Dahan R; Osorio JC; Fox BA; Ravetch JV
    Cancer Immunol Res; 2024 Mar; 12(3):322-333. PubMed ID: 38147316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodies.
    Knorr D; Leidner R; Jensen S; Meng R; Jones A; Ballesteros-Merino C; Bell RB; Baez M; Sprott D; Bifulco C; Piening B; Dahan R; Fox BA; Ravetch J
    bioRxiv; 2023 Jan; ():. PubMed ID: 36711504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8
    Semmrich M; Marchand JB; Fend L; Rehn M; Remy C; Holmkvist P; Silvestre N; Svensson C; Kleinpeter P; Deforges J; Junghus F; Cleary KL; Bodén M; Mårtensson L; Foloppe J; Teige I; Quéméneur E; Frendéus B
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3
    Sharma A; Subudhi SK; Blando J; Scutti J; Vence L; Wargo J; Allison JP; Ribas A; Sharma P
    Clin Cancer Res; 2019 Feb; 25(4):1233-1238. PubMed ID: 30054281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy.
    Sato Y; Casson CN; Matsuda A; Kim JI; Shi JQ; Iwasaki S; Chen S; Modrell B; Chan C; Tavares D; Austen D; Ida K; Tayber O; Hein P; Comeau R; Lin Y; Shaw MH
    Cancer Immunol Immunother; 2022 Oct; 71(10):2421-2431. PubMed ID: 35237846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual targeting of CTLA-4 and CD47 on T
    Zhang A; Ren Z; Tseng KF; Liu X; Li H; Lu C; Cai Y; Minna JD; Fu YX
    Sci Transl Med; 2021 Aug; 13(605):. PubMed ID: 34349035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
    Sanseviero E; O'Brien EM; Karras JR; Shabaneh TB; Aksoy BA; Xu W; Zheng C; Yin X; Xu X; Karakousis GC; Amaravadi RK; Nam B; Turk MJ; Hammerbacher J; Rubinstein MP; Schuchter LM; Mitchell TC; Liu Q; Stone EL
    Cancer Immunol Res; 2019 Aug; 7(8):1371-1380. PubMed ID: 31239316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
    Arce Vargas F; Furness AJS; Litchfield K; Joshi K; Rosenthal R; Ghorani E; Solomon I; Lesko MH; Ruef N; Roddie C; Henry JY; Spain L; Ben Aissa A; Georgiou A; Wong YNS; Smith M; Strauss D; Hayes A; Nicol D; O'Brien T; Mårtensson L; Ljungars A; Teige I; Frendéus B; ; ; ; Pule M; Marafioti T; Gore M; Larkin J; Turajlic S; Swanton C; Peggs KS; Quezada SA
    Cancer Cell; 2018 Apr; 33(4):649-663.e4. PubMed ID: 29576375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
    Du X; Tang F; Liu M; Su J; Zhang Y; Wu W; Devenport M; Lazarski CA; Zhang P; Wang X; Ye P; Wang C; Hwang E; Zhu T; Xu T; Zheng P; Liu Y
    Cell Res; 2018 Apr; 28(4):416-432. PubMed ID: 29472691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An anti-CTLA-4 heavy chain-only antibody with enhanced T
    Gan X; Shan Q; Li H; Janssens R; Shen Y; He Y; Chen F; van Haperen R; Drabek D; Li J; Zhang Y; Zhao J; Qin B; Jheng MJ; Chen V; Wang J; Rong Y; Grosveld F
    Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2200879119. PubMed ID: 35925889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer.
    Jenkins KA; Park M; Pederzoli-Ribeil M; Eskiocak U; Johnson P; Guzman W; McLaughlin M; Moore-Lai D; O'Toole C; Liu Z; Nicholson B; Flesch V; Qiu H; Clackson T; O'Hagan RC; Rodeck U; Karow M; O'Neil J; Williams JC
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38164757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies.
    Lax BM; Palmeri JR; Lutz EA; Sheen A; Stinson JA; Duhamel L; Santollani L; Kennedy A; Rothschilds AM; Spranger S; Sansom DM; Wittrup KD
    Proc Natl Acad Sci U S A; 2023 Aug; 120(31):e2300895120. PubMed ID: 37487077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs.
    Guo C; Dai X; Du Y; Xiong X; Gui X
    Cancer Immunol Immunother; 2024 Aug; 73(10):210. PubMed ID: 39123089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity.
    Watanabe T; Ishino T; Ueda Y; Nagasaki J; Sadahira T; Dansako H; Araki M; Togashi Y
    Cancer Sci; 2023 May; 114(5):1859-1870. PubMed ID: 36762794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic depletion of CCR8
    Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody.
    Roider HG; Hoff S; Tseng SY; Berndt S; Trautwein M; Filarsky K; Gritzan U; Camps J; Nadler WM; Grudzinska-Goebel J; Ellinger P; Pesch T; Soon CF; Geyer M; Gluske K; Stelte-Ludwig B; Gorjánácz M
    Clin Exp Med; 2024 Jun; 24(1):122. PubMed ID: 38856863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fc-Silent Anti-TIGIT Antibodies Potentiate Antitumor Immunity without Depleting Regulatory T Cells.
    Piovesan D; de Groot AE; Cho S; Anderson AE; Ray RD; Patnaik A; Foster PG; Mitchell CG; Lopez Espinoza AY; Zhu WS; Stagnaro CE; Singh H; Zhao X; Seitz L; Walker NP; Walters MJ; Sivick KE
    Cancer Res; 2024 Jun; 84(12):1978-1995. PubMed ID: 38635895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling.
    Yofe I; Landsberger T; Yalin A; Solomon I; Costoya C; Demane DF; Shah M; David E; Borenstein C; Barboy O; Matos I; Peggs KS; Quezada SA; Amit I
    Nat Cancer; 2022 Nov; 3(11):1336-1350. PubMed ID: 36302895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer.
    Schofield DJ; Percival-Alwyn J; Rytelewski M; Hood J; Rothstein R; Wetzel L; McGlinchey K; Adjei G; Watkins A; Machiesky L; Chen W; Andrews J; Groves M; Morrow M; Stewart RA; Leinster A; Wilkinson RW; Hammond SA; Luheshi N; Dobson C; Oberst M
    MAbs; 2021; 13(1):1857100. PubMed ID: 33397194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CTLA-4 antibody ipilimumab negatively affects CD4
    Rosskopf S; Leitner J; Zlabinger GJ; Steinberger P
    Cancer Immunol Immunother; 2019 Aug; 68(8):1359-1368. PubMed ID: 31332464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.